Literature DB >> 1772877

Non-radioactive oligotyping for HLA-DR1-DRw10 using polymerase chain reaction, digoxigenin-labelled oligonucleotides and chemiluminescence detection.

C Nevinny-Stickel1, M Hinzpeter, A Andreas, E D Albert.   

Abstract

We describe a rapid non-radioactive DNA typing of the serological types DR1-DRw10 using polymerase chain reaction (PCR)-amplified DNA and 15 sequence-specific oligonucleotides (SSO) which are labelled enzymatically at their 3' end with one digoxigenin (DIG). The hybridized SSOs were detected using anti-DIG alkaline phosphatase and Fab fragments and visualization was obtained with the chemiluminescent substate 3-(2'-spiroadamantan)-4-(3''-phosphoryloxy)-phenyl-1,2-di o xetan (AMPPD). The results were identical with those of the previously used 5-bromo-4-chloro-3-indolyl-phosphate (BCIP)/4-nitrobluetetrazolium chloride (NBT) system. The use of AMPPD is more rapid and allows the repeated rehybridization of the membrane-bound DNA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772877     DOI: 10.1111/j.1744-313x.1991.tb00032.x

Source DB:  PubMed          Journal:  Eur J Immunogenet        ISSN: 0960-7420


  10 in total

1.  p53 gene mutations are not required for early dissemination of cancer cells.

Authors:  S Offner; W Schmaus; K Witter; G B Baretton; G Schlimok; B Passlick; G Riethmüller; K Pantel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  DR2 haplotypes (DRB1, DQA1, DQB1) associated with systemic lupus erythematosus.

Authors:  M P Bettinotti; K Hartung; H R Deicher; E Keller; S Mikschl; E Albert
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

3.  DNA-based HLA class II postmortem typing: evaluation of different techniques for prospective corneal allografting.

Authors:  S Jenisch; E Westphal; N Zavazava; C Dürr; G Duncker; B Nölle; W Müller-Ruchholtz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-10       Impact factor: 3.117

4.  Immunogenetic studies on HLA-DR in German coal miners with and without coal worker's pneumoconiosis.

Authors:  H P Rihs; P Lipps; K May-Taube; D Jäger; E W Schmidt; J H Hegemann; X Baur
Journal:  Lung       Date:  1994       Impact factor: 2.584

5.  HLA class II DRB1 and DQB1 allelic polymorphism and sclerosing lymphocytic lobulitis of the breast.

Authors:  A H Lee; A C Bateman; S J Turner; J M Theaker; W M Howell
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

6.  Polymorphism of the DQA1 promoter region (QAP) and DRB1, QAP, DQA1, DQB1 haplotypes in systemic lupus erythematosus. SLE Study Group members.

Authors:  Z Yao; A Kimura; K Hartung; P J Haas; A Volgger; G Brünnler; J Bönisch; E D Albert
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

7.  HLA-DP/DR interaction in early onset pauciarticular juvenile chronic arthritis.

Authors:  C Paul; U Schoenwald; H Truckenbrodt; M P Bettinotti; G Brünnler; E Keller; C Nevinny-Stickel; Z Yao; E D Albert
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

8.  No direct correlation between HLA-DPB1 and antibodies against recombinant Ro (SS-A)/La (SS-B) proteins in systemic lupus erythematosus. SLE Study Group.

Authors:  Z Yao; K Hartung; H Ehrfeld; H P Seelig; H G Deicher; G Brünnler; E Keller; E Albert
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

9.  HLA class II genes and antibodies against recombinant U1-nRNP proteins in patients with systemic lupus erythematosus. SLE Study Group.

Authors:  Z Yao; H P Seelig; H Ehrfeld; M Renz; K Hartung; H Deicher; E Keller; C Nevinny-Stickel; E D Albert
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

10.  Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.

Authors:  A Valli; A Sette; L Kappos; C Oseroff; J Sidney; G Miescher; M Hochberger; E D Albert; L Adorini
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.